Article not rated

Vol. 10 - Num. 39

Brief Reports

The heptavalent pneumococcal conjugate vaccine: lights and shades?

Miguel Ángel San José Gonzáleza, P Méndez Fernándezb

aPediatra. Servicio de Atención Primaria. Sarria. Lugo. España.
bPediatra. Servicio de Atención Primaria Illas Canarias. Servizo Galego de Saúde. Gerencia de Atención Primaria. Lugo. España.

Correspondence: MÁ San José. E-mail:

Reference of this article: San José González MÁ, Méndez Fernández P. The heptavalent pneumococcal conjugate vaccine: lights and shades? Rev Pediatr Aten Primaria. 2008;10:467-88.

Published in Internet: 30-09-2008 - Visits: 6576


The heptavalent pneumococcal conjugate vaccine has proved a high efficacy, not only to reduce the incidence of invasive pneumococcal disease in children, but also in the decrease of resistance to antibiotics and nasopharyngeal colonization, which affects older age groups. The publication of papers that show an increase of isolates of non-vaccine serotypes, mainly 19A, but with an impact on the disease still unimportant, casts shadows in the above picture of success vaccine. We propose a review of recent literature with the aim of providing an overview of both the current vaccine, as well as the potential disputes.


Heptavalent pneumococcal conjugate Paediatrics Streptococcus pneumoniae

This content is not available in html format but you may download it in Acrobat Reader (PDF).


This article has no comments yet.